Chronic Coronary Disease (CCD)

Details of the Concept

Chronic coronary disease (CCD) is an umbrella term for stable outpatient presentations of coronary artery disease. It encompasses patients post-ACS/revascularisation once stabilised, those with ischaemic cardiomyopathy, stable angina syndromes managed medically, coronary vasospasm or microvascular angina (INOCA), and coronary disease detected incidentally on screening. CCD represents a clinical continuum from the acute phase of ACS into long-term outpatient management. Approximately 20.1 million Americans have CCD; it remains the leading cause of death in the US and worldwide despite an ~25% relative decline in CHD death over the past decade.

Key Facts

Epidemiology

• ~20.1 million persons in the US have CCD; 11.1 million have chronic stable angina; 8.8 million have had a prior MI (sources/CCS-AHA-2023, rating: very high)
• 25% of all MIs in the US (~200,000 annually) occur in persons with prior MI — "recurrent MI" population (sources/CCS-AHA-2023, rating: very high)
• Prevalence varies by age, sex, race, ethnicity, and geography; NH Black women have CHD prevalence 7.2% — higher than NH White women (6.0%) (sources/CCS-AHA-2023, rating: very high)
• Social determinants of health (SDOH) — health care access, economic stability, neighbourhood environment — are key drivers of outcomes in CCD and must be systematically assessed (sources/CCS-AHA-2023, rating: very high)

Risk Stratification

• Integrate results of noninvasive/invasive testing with clinical, social, and demographic variables using validated risk models (sources/CCS-AHA-2023, rating: very high)
• Three annual risk categories for CV death or nonfatal MI: low (<1%), intermediate (1–3%), high (>3%)
• Routine ICA for asymptomatic stable patients not recommended — COR 3 No Benefit/A (COURAGE, BARI-2D, ISCHEMIA) (sources/CCS-AHA-2023, rating: very high)
• Functional testing recommended for patients with change in symptoms/functional status despite GDMT — COR 1/B-NR (sources/CCS-AHA-2023, rating: very high)

Beta Blockers — Paradigm Change

• COR 1/A: LVEF ≤40% with or without prior MI — reduces future MACE and CV death; metoprolol succinate, carvedilol, or bisoprolol preferred (sources/CCS-AHA-2023, rating: very high)
• COR 2b/B-NR: Prior MI, LVEF >50%, ≤1 year — reasonable to reassess need for long-term (>1 year) beta blocker if no angina, arrhythmia, or uncontrolled hypertension; multiple ongoing RCTs (REBOOT-CNIC, REDUCE-SWEDEHEART, BETAMI, DANBLOCK) (sources/CCS-AHA-2023, rating: very high)
• COR 3 No Benefit/B-NR: No prior MI, LVEF >50%, no other indication — beta blockers do NOT reduce MACE in this population; REACH registry, NCDR CathPCI, and CHARISMA post-hoc analysis consistently negative (sources/CCS-AHA-2023, rating: very high)

Guideline-Directed Medical Therapy (GDMT) Highlights

• High-intensity statin COR 1/A: ≥50% LDL-C reduction; generic formulations are cost-saving; monitor at 4–12 weeks then 3–12 monthly (sources/CCS-AHA-2023, rating: very high)
• Ezetimibe (COR 2a) + PCSK9 mAb (COR 2a/A) for very high risk (LDL ≥70 on max statin ± ezetimibe): see concepts/Dyslipidemia-Management (sources/CCS-AHA-2023, rating: very high)
• SGLT2i + GLP-1 RA COR 1/A for CCD + T2DM: SGLT2i primarily reduces HF/CKD progression; GLP-1 RA primarily reduces atherosclerotic events; dual therapy may be additive (sources/CCS-AHA-2023, rating: very high)
• SGLT2i COR 1/A for HFrEF (LVEF ≤40%) regardless of DM; COR 2a/B-R for HFpEF (sources/CCS-AHA-2023, rating: very high)
• BP target <130/<80 mmHg COR 1/B-R: ACEi/ARB or beta blocker first-line for compelling indications (recent MI, angina, LVEF ≤40%) (sources/CCS-AHA-2023, rating: very high)
• ACEi/ARB COR 1/A: HTN + DM + LVEF ≤40% + CKD; COR 2b/B-R without these comorbidities (sources/CCS-AHA-2023, rating: very high)

Antiplatelet Strategy in Chronic CCD

• Aspirin 81 mg daily COR 1/A: Secondary prevention — 81 mg non-inferior to 325 mg with fewer bleeds (ADAPTABLE trial) (sources/CCS-AHA-2023, rating: very high)
• DAPT 6 months post-PCI → SAPT COR 1/A: Meta-analysis (n=31,666): similar MACE, lower bleeding vs 12-month DAPT; aspirin continued indefinitely (sources/CCS-AHA-2023, rating: very high)
• P2Y12 monotherapy after 1–3 months DAPT COR 2a/A: SMART CHOICE, STOP-DAPT2, TWILIGHT, GLOBAL LEADERS — reduced bleeding without increased ischaemic events (sources/CCS-AHA-2023, rating: very high)
• Extended DAPT >12 months (up to 3 years) for prior MI + low bleeding COR 2b/A: PEGASUS-TIMI 54 — ticagrelor 60 mg BID: 16% reduction in CV death/MI/stroke; NNT ~91; increased major bleeding (sources/CCS-AHA-2023, rating: very high)
• Low-dose rivaroxaban 2.5 mg BID + aspirin COR 2a/B-R: High ischaemic risk, low-moderate bleeding, no OAC/DAPT indication — COMPASS trial: composite CV death/stroke/MI 4.1% vs 5.4%; major bleeding higher (3.1% vs 1.9%) (sources/CCS-AHA-2023, rating: very high)
• See concepts/DAPT-Strategies for full antiplatelet strategy details (sources/CCS-AHA-2023, rating: very high)

Colchicine

• COR 2b/B-R: 0.5 mg daily for secondary prevention of recurrent ASCVD events
• LoDoCo2 (stable ASCVD): 6.8% vs 9.6% primary MACE (P<0.001); trend toward excess noncardiovascular death in colchicine group
• COLCOT (post-ACS): 5.5% vs 7.1% primary MACE (P=0.02) — primarily stroke and urgent revascularisation
• Avoid: eGFR <30 mL/min/m²; CYP3A4 interactions; use in highest remaining-risk patients only (sources/CCS-AHA-2023, rating: very high)

Antianginal Therapy

• First-line COR 1/B-R: Beta blocker OR CCB OR long-acting nitrate — equal evidence for angina relief; no difference in mortality
• Combination COR 1/B-R: Add second agent from different class if persistent angina
• Ranolazine COR 1/B-R: If angina persists on beta blocker/CCB/nitrate (CARISA, ERICA trials)
• Ivabradine COR 3 Harm: In CCD with normal LV function — BEAUTIFUL trial: 7.6% vs 6.5% primary endpoint (CV death/MI; P=0.02); harm signal (sources/CCS-AHA-2023, rating: very high)

Revascularisation — The ISCHEMIA Paradigm

• Stable CCD without severe LV dysfunction or left main disease: No survival benefit from routine revascularisation — COURAGE, BARI-2D, ISCHEMIA all confirm null effect on all-cause death and MACE at 3–4 years; ISCHEMIA 7-year: late CV mortality benefit in invasive arm (sources/CCS-AHA-2023, rating: very high)
• Revascularisation COR 1/A for lifestyle-limiting angina despite GDMT — symptom improvement confirmed (ISCHEMIA: higher Seattle Angina Questionnaire scores sustained ×36 months in invasive arm, greatest in daily/weekly angina at baseline) (sources/CCS-AHA-2023, rating: very high)
• CABG for LV dysfunction (LVEF ≤35%) — COR 1/B-R: STICH trial (n=1,212): CABG + medical therapy — lower CV death (28% vs 33%; P=0.05) and all-cause death at 10 years vs medical therapy alone (sources/CCS-AHA-2023, rating: very high)
• PCI for LVEF ≤35% — no survival benefit: REVIVED-BCIS2 (n=700, LVEF ≤35%): PCI + GDMT vs GDMT alone — no difference in all-cause death or HF hospitalisation at 3.4 years (sources/CCS-AHA-2023, rating: very high)
• CABG preferred over PCI for: (1) Left main + SYNTAX >33 (COR 1/B-R); (2) Multivessel + SYNTAX >33 (COR 2a/B-R); (3) Diabetes + multivessel + LAD involvement (COR 1/A; FREEDOM: HR 1.36 for PCI at 8 years) (sources/CCS-AHA-2023, rating: very high)
• FFR/iFR before PCI for intermediate stenoses — COR 1/A: FAME-2: FFR-guided PCI superior to medical therapy for urgent revascularisation reduction, sustained ×5 years; high economic value (<$50K/QALY) (sources/CCS-AHA-2023, rating: very high)
• Heart Team required COR 1/B-NR: Complex 3-vessel or left main disease (sources/CCS-AHA-2023, rating: very high)

INOCA (Ischaemia with Nonobstructive Coronary Arteries)

• 50% of patients undergoing elective coronary angiography have nonobstructive CAD; associated with increased death and MI risk (sources/CCS-AHA-2023, rating: very high)

• COR 2a/B-R: Invasive coronary physiology-guided stratified medical therapy — CorMicA trial: +11.7 units Seattle Angina Questionnaire at 6 months vs standard care
• Endotypes: microvascular angina (IMR ≥25, CFR <2.0); vasospastic angina (>90% epicardial constriction with acetylcholine); mixed; noncardiac
• Endotype-specific therapy: microvascular → beta blocker first, then CCB, then ranolazine; vasospastic → CCB first, then long-acting nitrate (sources/CCS-AHA-2023, rating: very high)

Spontaneous Coronary Artery Dissection (SCAD)

• Underrecognised cause of MI; more common in young women with low classical ASCVD risk; recurrence up to 27% at 5 years (sources/CCS-AHA-2023, rating: very high)
• Conservative management preferred acutely; CR COR 1/C-LD; beta blockers COR 2b/C-LD (64% reduction in recurrent SCAD in observational study)
• Screen for fibromuscular dysplasia and extracoronary arteriopathies — COR 2a/C-LD (sources/CCS-AHA-2023, rating: very high)

Contradictions / Open Questions

• Beta-blocker de-escalation evidence gap: COR 3 No Benefit for prior MI + preserved EF + >1 year is based on observational data only; RCTs (REBOOT-CNIC, REDUCE-SWEDEHEART, BETAMI, DANBLOCK) were ongoing at guideline publication. If these trials show a mortality benefit in a subgroup, the recommendation may need revision. (sources/CCS-AHA-2023, rating: very high)
• Colchicine noncardiovascular death signal: LoDoCo2 showed a trend toward increased noncardiovascular mortality; mechanism unknown; not replicated in COLCOT or ACS subgroups. Long-term safety in CCD requires further evaluation. (sources/CCS-AHA-2023, rating: very high)
• ISCHEMIA late benefit discordance: No MACE benefit at 3–4 years; but CV mortality reduction at 7 years in invasive arm. Whether this represents a late protective effect or statistical fluctuation is unresolved. (sources/CCS-AHA-2023, rating: very high)
• Icosapent ethyl REDUCE-IT mineral oil placebo controversy: Consistent with concepts/Dyslipidemia-Management contradiction — ACC/AHA 2023 CCD gives only COR 2b; REDUCE-IT mineral oil may have inflated benefit estimate. (sources/CCS-AHA-2023, rating: very high)
• Inclisiran MACE data: Bempedoic acid and inclisiran listed as COR 2b options — CLEAR Outcomes (bempedoic acid MACE reduction 13%) published after guideline; inclisiran CVOT still ongoing. Future guideline update may upgrade bempedoic acid to COR 2a or higher. (sources/CCS-AHA-2023, rating: very high)
• When to discontinue aspirin in AFIRE-type CCD + AF patients: AFIRE shows rivaroxaban monotherapy noninferior to rivaroxaban + antiplatelet in stable CCD + AF >1 year post-PCI; however DOAC monotherapy COR only 2b/C-LD when there is no acute indication. (sources/CCS-AHA-2023, rating: very high)

Connections

• Related to entities/Acute-Coronary-Syndrome — CCD is the chronic phase of ACS; same patient continuum
• Related to concepts/DAPT-Strategies — antiplatelet management for both acute and chronic coronary phases
• Related to concepts/Dyslipidemia-Management — very high risk definition; stepwise LDL-C lowering
• Related to entities/Heart-Failure — ischaemic cardiomyopathy; CABG/SGLT2i/beta-blocker management
• Related to entities/Atrial-Fibrillation — anticoagulation in CCD + AF; AFIRE trial
• Related to concepts/ASCVD-Risk-Assessment — PREVENT model; risk-guided therapy
• Related to concepts/Right-Heart-Catheterization — haemodynamic assessment in INOCA and ischaemic HF

Sources

• sources/CCS-AHA-2023